Active — Not RecruitingPhase 2

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

United States40 participantsStarted 2023-07-01

Plain-language summary

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder.
✓. Age 50+ (60+ for depression).
✓. Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging).
✓. No history of dementia by patient report.
✓. Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression.

Exclusion criteria

✕. Contraindications for dasatinib or quercetin
✕. Active SI such that participant could not be safely managed in an outpatient clinical trial.
✕. Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin).
✕. All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.

What they're measuring

Number of participants who successfully completed and safely tolerated the intervention

Timeframe: 10 weeks

Trial details

NCT IDNCT05838560

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10-01

View on ClinicalTrials.gov More Schizophrenia trials